2011
DOI: 10.1016/j.humpath.2010.05.023
|View full text |Cite
|
Sign up to set email alerts
|

Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

11
153
5

Year Published

2013
2013
2020
2020

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 139 publications
(169 citation statements)
references
References 40 publications
11
153
5
Order By: Relevance
“…The present study identified an association of SIRT1 overexpression with shorter OS time and poor prognostic indicators in SCC, which was consistent with the results of previous studies (4,36,45). By contrast, certain reports have found a significant association between SIRT1 overexpression and more favorable prognosis in serous carcinoma of the ovary (46) and colorectal cancer (47,48).…”
Section: A B C Dsupporting
confidence: 93%
See 1 more Smart Citation
“…The present study identified an association of SIRT1 overexpression with shorter OS time and poor prognostic indicators in SCC, which was consistent with the results of previous studies (4,36,45). By contrast, certain reports have found a significant association between SIRT1 overexpression and more favorable prognosis in serous carcinoma of the ovary (46) and colorectal cancer (47,48).…”
Section: A B C Dsupporting
confidence: 93%
“…malignancies (6,42), and changes in SIRT1-mediated signaling allows mammalian cells to survive under oxidative stress and DNA damage, which are closely associated with tumorigenesis (43,44), cancer progression and poor prognosis in cancer patients (3,4,36). The present study identified an association of SIRT1 overexpression with shorter OS time and poor prognostic indicators in SCC, which was consistent with the results of previous studies (4,36,45).…”
Section: A B C Dsupporting
confidence: 92%
“…DBC1 potentiates ERα transcriptional activity by inhibiting the association of sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide-dependent deacetylase, with both ERα and the SIRT1-mediated deacetylation of ERα. DBC1 and SIRT1 expression correlates with more distant metastatic relapses and a shorter period of relapse-free survival in breast cancer patients [181]. Ciz1 is a novel coactivator of ERα involved in DNA replication and cell cycle regulation.…”
Section: Estrogen Receptor Coregulators In Breast Cancer Coactivatorsmentioning
confidence: 99%
“…Correlations of SIRT1 expression with clinico-pathological features in different cancer types and with patients prognosis also suggest different contribution of SIRT1 to cancer outcome, including responses to therapy. SIRT1 overexpression positively correlates with poor prognosis in B cell lymphoma [15], gastric cancer [16] and breast cancer [17], while it is related to favorable outcome in ovarian epithelial cancer [18]. Currently, the molecular background that determines participation of SIRT1 to tumor development and responses to the therapy is yet to be clarified.…”
Section: Introductionmentioning
confidence: 99%